The Federal Drug Administration has given accelerated approval to aducanumab as a treatment for Alzheimer’s disease, while asking the manufacturer, Biogen, to conduct a phase 4 confirmatory trial. ‘There remains some uncertainty,’ according to the director of the FDA Center for Drug Evaluation and Research, ‘about the drug’s clinical benefit.’
‘Old age’, ‘senile dementia’, ‘cerebrovascular disease’ and ‘Alzheimer’s disease’ are all designations of a process of dementia that occurs in older people. The name has changed over time in subsequent editions of the International Classification of Diseases.
Read more about What do you call it?